Literature DB >> 24957661

Where did platelets go in 2012? A survey of platelet transfusion practice in the North of England.

A Charlton1, J Wallis, J Robertson, D Watson, A Iqbal, H Tinegate.   

Abstract

OBJECTIVES: To record the fate of transfused platelet doses in the North of England, and thereby assist with demand-planning and help target teaching on appropriate use.
BACKGROUND: Platelet use has risen recently to the extent that donation practice has changed to meet demand. Two national comparative audits have shown inappropriate use and the 2010 audit concluded that current U.K. guidelines for platelet usage should be completely implemented at a local level. It is necessary to know how platelets are used and by whom in order to facilitate guideline concordance.
METHODS: All hospital trusts in the North East and Cumbria recorded data on all platelet doses transfused in two separate 4-week periods in 2012. Data were entered onto an electronic survey tool.
RESULTS: One thousand and five hundred and seventy-four reports were received, documenting 1937 transfused doses--96% of total issues for the study periods. One thousand and forty-five platelet doses (54%) were given for haematological indications. The second commonest indication was cardiac surgery (201 doses, 10% of the total) followed by non-haematological oncology (127 doses, 6.5%), critical care (106 doses, 5%) and liver disease (50 doses, 2.5%). The commonest haematological indication was acute myeloid leukaemia, 310 doses, (16% of all platelet use), followed by stem cell transplantation, 271 doses (14%). Seventy-two percent of platelet doses were given prophylactically, the majority without any planned procedure.
CONCLUSION: The commonest indication for platelet use, where reinforcement of guidelines will be productive, is prophylaxis in haematological disease. Use of platelets in cardiac surgery is also worthy of close scrutiny.
© 2014 The Authors. Transfusion Medicine © 2014 British Blood Transfusion Society.

Entities:  

Keywords:  appropriate use; indications; platelets; prophylactic

Mesh:

Year:  2014        PMID: 24957661     DOI: 10.1111/tme.12126

Source DB:  PubMed          Journal:  Transfus Med        ISSN: 0958-7578            Impact factor:   2.019


  9 in total

Review 1.  Pathogen-reduced platelets for the prevention of bleeding.

Authors:  Lise J Estcourt; Reem Malouf; Sally Hopewell; Marialena Trivella; Carolyn Doree; Simon J Stanworth; Michael F Murphy
Journal:  Cochrane Database Syst Rev       Date:  2017-07-30

2.  Blood Product Supply in Germany: The Impact of Apheresis and Pooled Platelet Concentrates.

Authors:  Karin Berger; Dorothee Schopohl; Georg Wittmann; Wolfgang Schramm; Helmut Ostermann; Christina Rieger
Journal:  Transfus Med Hemother       Date:  2016-09-15       Impact factor: 3.747

Review 3.  There and back again: the once and current developments in donor-derived platelet products for hemostatic therapy.

Authors:  Valery J Kogler; Moritz Stolla
Journal:  Blood       Date:  2022-06-30       Impact factor: 25.476

Review 4.  Quality Assessment of Established and Emerging Blood Components for Transfusion.

Authors:  Jason P Acker; Denese C Marks; William P Sheffield
Journal:  J Blood Transfus       Date:  2016-12-14

5.  Bleeding risk of surgery and its prevention in patients with inherited platelet disorders.

Authors:  Sara Orsini; Patrizia Noris; Loredana Bury; Paula G Heller; Cristina Santoro; Rezan A Kadir; Nora C Butta; Emanuela Falcinelli; Ana Rosa Cid; Fabrizio Fabris; Marc Fouassier; Koji Miyazaki; Maria Luisa Lozano; Pamela Zúñiga; Claire Flaujac; Gian Marco Podda; Nuria Bermejo; Remi Favier; Yvonne Henskens; Emmanuel De Maistre; Erica De Candia; Andrew D Mumford; Gul Nihal Ozdemir; Ibrahim Eker; Paquita Nurden; Sophie Bayart; Michele P Lambert; James Bussel; Barbara Zieger; Alberto Tosetto; Federica Melazzini; Ana C Glembotsky; Alessandro Pecci; Marco Cattaneo; Nicole Schlegel; Paolo Gresele
Journal:  Haematologica       Date:  2017-04-06       Impact factor: 9.941

6.  Platelet transfusion and tranexamic acid to prevent bleeding in outpatients with a hematological disease: A Dutch nationwide survey.

Authors:  Loes L Cornelissen; Camila Caram-Deelder; Romy T Meier; Jaap Jan Zwaginga; Dorothea Evers
Journal:  Eur J Haematol       Date:  2020-12-21       Impact factor: 2.997

7.  Inhibition of Dendritic Cell Activation and Modulation of T Cell Polarization by the Platelet Secretome.

Authors:  Anno Saris; Juulke Steuten; David P Schrijver; Gijs van Schijndel; Jaap Jan Zwaginga; S Marieke van Ham; Anja Ten Brinke
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

8.  A nationwide survey of clinical use of blood in Italy.

Authors:  Giuseppina Facco; Francesco Bennardello; Francesco Fiorin; Claudia Galassi; Chiara Monagheddu; Pierluigi Berti
Journal:  Blood Transfus       Date:  2021-08-05       Impact factor: 3.443

9.  Protein Concentrations in Stored Pooled Platelet Concentrates Treated with Pathogen Inactivation by Amotosalen Plus Ultraviolet a Illumination.

Authors:  Niels Arni Arnason; Freyr Johannsson; Ragna Landrö; Björn Hardarsson; Sveinn Gudmundsson; Aina-Mari Lian; Janne Reseland; Ottar Rolfsson; Olafur E Sigurjonsson
Journal:  Pathogens       Date:  2022-03-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.